Conditional Approval For Trexima

Pozen Inc. (POZN) and GlaxoSmithKline PLC (GSK) received conditional approval from Food and Drug Administration for their migraine medication Trexima. Additional safety information must be provided to the regulatory agency before full approval is granted. Shares of Pozen plummeted $8.59 to close at $5.52 while GlaxoSmithKline stock eased 75 cents to close at $54.65.